Improving Glycemic Control on GMS: A Quality Improvement Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

179 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine whether new processes and technologies for monitoring diabetic patients' insulin levels improves patient care at Brigham and Women's Hospital.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Glucose Monitoring Methods: Characterizing Glycemic Control in Subjects With Diabetes

NCT00805506

Diabetes

COMPLETED

Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS)

NCT01763567

Hyperglycemia

COMPLETED

Evaluation of the Accuracy and Safety of A Novel Real-Time Continuous Glucose Monitoring System

NCT07092761

Type1diabetes

RECRUITING NA

Inpatient Use of Personal Continuous Glucose Monitor (CGM) to Improve Diabetes Mellitus Control

NCT07006480

Diabetes Mellitus

RECRUITING NA

Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food

NCT00818077

Type 2 Diabetes Currently Taking Metformin

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will examine whether new processed and technologies for monitoring diabetic patients' insulin levels improves patient care. Patients at Brigham and Women's Hospital (BWH), staying on the General Medicine Service, who have Type 2 diabetes and who are not on IV insulin can participate in this study. Physicians and nurses will be taught new rules to care for diabetic patients, while in the hospital. Also, the BWH computer system will be updated to include these new rules for administering insulin. Patients who participate in the study will be randomly placed into one of two groups: one group that will be cared for by physicians and nurses who have learned these new rules for administering insulin; or the second group, who will receive diabetes care at BWH before the new rules were adopted. The study will last approximately 1 year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Usual Care

admission to medical team floor to usual care

Group Type NO_INTERVENTION

No interventions assigned to this group

Intervention

consists of usual care as well as an admission order set built into BWH's proprietary computer provider order entry (CPOE) system

Group Type EXPERIMENTAL

Order Set, Education, Feedback

Intervention Type BEHAVIORAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Order Set, Education, Feedback

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects will include all type 2 diabetic patients on the General Medicine Service (GMS) of Brigham and Women's Hospital (BWH) who do not have an indication for IV insulin.